先声药业（股票代码：02096）近日宣布，已与全球知名药企勃林格殷格翰（Boehringer Ingelheim）签署授权协议，将旗下创新药Sim0709在大中华区以外的全球独家开发、生产和商业化权利授予后者。
Sim0709是先声药业自主研发的一款小分子抑制剂，目前处于临床前研究阶段，潜在适应症涵盖肿瘤领域。根据协议条款，勃林格殷格翰将获得该药物在中国大陆、香港、澳门及台湾地区以外的独家权益，并承担后续研发及市场推广的全部费用。先声药业有望获得包括首付款、里程碑付款及销售分成在内的多项收益。
此次合作标志着先声药业的创新研发能力获得国际认可，也为公司拓展全球市场奠定基础。勃林格殷格翰凭借其强大的商业化网络，有望加速Sim0709的国际化进程。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.